StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$31.73+1.94 (+6.51%)

Close on Nov 19, 2026Market cap $1.55BP/E –Yield –

UroGen Pharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

UroGen Pharma's revenue for the twelve months ending Jun 30, 2026 was $188.73M, up 100.3% year over year. For fiscal 2025 it was $109.79M, up 21.4% from the year before. The highest annual figure on record is $109.79M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$109.79M+21.4%
FY2024Dec 31, 2024$90.40M+9.3%
FY2023Dec 31, 2023$82.71M+28.5%
FY2022Dec 31, 2022$64.36M+34.0%
FY2021Dec 31, 2021$48.04M+307.2%
FY2020Dec 31, 2020$11.80M+65450.0%
FY2019Dec 31, 2019$18.00K-98.4%
FY2018Dec 31, 2018$1.13M-86.2%
FY2017Dec 31, 2017$8.16M-53.5%
FY2016Dec 31, 2016$17.53M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$72.46M+199.2%
Q1 FY2026Mar 31, 2026$50.96M+151.6%
Q4 FY2025Dec 31, 2025$37.84M+54.0%
Q3 FY2025Sep 30, 2025$27.48M+9.0%
Q2 FY2025Jun 30, 2025$24.22M+10.8%
Q1 FY2025Mar 31, 2025$20.25M+7.8%
Q4 FY2024Dec 31, 2024$24.57M+4.4%
Q3 FY2024Sep 30, 2024$25.20M+20.9%
Q2 FY2024Jun 30, 2024$21.85M+3.4%
Q1 FY2024Mar 31, 2024$18.78M+9.2%
Q4 FY2023Dec 31, 2023$23.53M+30.1%
Q3 FY2023Sep 30, 2023$20.85M+29.5%
Q2 FY2023Jun 30, 2023$21.14M+27.3%
Q1 FY2023Mar 31, 2023$17.19M+26.7%
Q4 FY2022Dec 31, 2022$18.09M+11.9%
Q3 FY2022Sep 30, 2022$16.10M+41.8%
Q2 FY2022Jun 30, 2022$16.60M+27.4%
Q1 FY2022Mar 31, 2022$13.56M+81.2%
Q4 FY2021Dec 31, 2021$16.17M+103.0%
Q3 FY2021Sep 30, 2021$11.35M+228.0%
Q2 FY2021Jun 30, 2021$13.03M+3403.2%
Q1 FY2021Mar 31, 2021$7.49M–
Q4 FY2020Dec 31, 2020$7.97M–
Q3 FY2020Sep 30, 2020$3.46M+19127.8%
Q2 FY2020Jun 30, 2020$372.00K–
Q4 FY2019Dec 31, 2019$0-100.0%
Q3 FY2019Sep 30, 2019$0-100.0%
Q2 FY2019Jun 30, 2019$18.00K-96.3%
Q4 FY2018Dec 31, 2018$0-100.0%
Q3 FY2018Sep 30, 2018$283.00K-96.4%
Q2 FY2018Jun 30, 2018$364.00K–
Q1 FY2018Mar 31, 2018$481.00K+2431.6%
Q4 FY2017Dec 31, 2017$327.00K–
Q3 FY2017Sep 30, 2017$7.81M–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$19.00K–

More UroGen Pharma figures

See a number that looks wrong?